MEN1611 With Trastuzumab (+/- Fulvestrant) in Metastatic Breast Cancer
Completed · Phase 1
Conditions studied: Advanced or Metastatic Breast Cancer
In brief
The main purpose of this open-label, dose-escalation, phase Ib study is to identify the appropriate dose of MEN1611 to be used in combination with Trastuzumab with/without Fulvestrant for the treatment of advanced or metastatic HER2-positive breast cancer
Key facts
- Study ID
- NCT03767335
- Run by
- Menarini Group
- People needed
- 62
- Starts
- 2018-11-13
- Expected to finish
- 2024-02-23
- Last updated by the study team
- 2025-06-26
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Holy Cross Hospital Inc. — Fort Lauderdale, Florida, United States
- Detroit Clinical Research Center — Farmington Hills, Michigan, United States
- Washington University — St Louis, Missouri, United States
- Cliniques Universitaires Saint-Luc — Brussels, Belgium
- Institut Jules Bordet — Brussels, Belgium
- UZ Leuven — Leuven, Belgium
- Centre Georges François Leclerc — Dijon, France
- Centre Oscar Lambret — Lille, France
- Institut Régional du Cancer de Montpellier — Montferrier-sur-Lez, France
- ICO - Site René Gauducheau — Saint-Herblain, France
- Institut Claudius Regaud Oncopole — Toulouse, France
- Institut Gustave Roussy — Villejuif, France
- Azienda Ospedaliero Universitaria Mater Domini — Catanzaro, Italy
- Istituto Clinico Humanitas — Milan, Italy
- Istituto Europeo di Oncologia (IEO) — Milan, Italy
- Ospedale San Raffaele — Milan, Italy
- Hospital Clínic i Provincial de Barcelona — Barcelona, Spain
- Hospital Universitari Vall d'Hebron — Barcelona, Spain
- Centro Integral Oncologico Clara Campal — Madrid, Spain
- Hospital General Universitario Gregorio Marañon — Madrid, Spain
- START Madrid Fundacion Jimenez Diaz — Madrid, Spain
- Hospital Clínico Universitario Virgen de la Victoria — Málaga, Spain
- Hospital Universitario Virgen del Rocío — Seville, Spain
- Velindre Cancer Centre — Cardiff, United Kingdom
- Sarah Cannon Research Institute UK — London, United Kingdom
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.